Get the Weekly Intelligence Brief — top committee picks every Sunday.

ACAD vs MCK

ACADIA Pharmaceuticals Inc. vs McKesson Corporation — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
62
Buy
VS
MCK
McKesson Corporation
57
Buy
MetricACADMCK
AI Score 62 57
Price $29.50 $860.44
P/E Ratio 13.11× 22.89×
ROE 31.9% -219.2%
Revenue Growth YoY
Gross Margin 91.1% 3.6%
Debt / Equity 0.06× -2.76×
Dividend Yield 0.0% 0.4%
RSI (14) 59.6 50.5
Beta 0.845 0.307
Expected Upside +4.1%

AI Committee View

Current Innellis committee reasoning for ACAD versus MCK.
ACAD leads by 5 points.

ACAD scores 62/100 (Buy) versus MCK at 57/100 (Buy).

ACAD Committee View
60% agreement
5 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 22.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • Bollinger bandwidth of 22.8% signals elevated volatility — Risk
MCK Committee View
67% agreement
6 analysts

The primary driver is news sentiment is positive (+0.27 across 20 articles, 14d). The main limiting factor is current ratio of 0.85 is tight -- limited short-term liquidity cushion. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 39.4% shows genuine earnings power backing the valuation — Value
  • EPS growing 49.1% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
  • Price-to-book of 4.3x prices in significant intangible value — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ACAD Full Analysis MCK Full Analysis